AskBio enters patent license agreement with Pfizer for HCV therapy

Sep 14 2010

Asklepios BioPharmaceutical, Inc. (AskBio), a privately-owned clinical-stage biotechnology company, announced today it has entered into a patent license agreement with Pfizer, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by AskBio, for use in developing novel therapies for patients with Hepatitis C virus (HCV). HCV infection is the most common chronic blood-borne infection in the United States, with approximately 3.2 million people chronically infected.

“This license represents another example of AskBio's progress in the development and commercialization of gene-delivery platform technology that focuses on creating value for a broad range of therapeutic options for patients, including those with HCV.”

"We are pleased to see our technology being used by Pfizer, which has a long-standing track record for excellence in the treatment of infectious diseases," said Jade Samulski, Director of Program Management at AskBio. "This license represents another example of AskBio's progress in the development and commercialization of gene-delivery platform technology that focuses on creating value for a broad range of therapeutic options for patients, including those with HCV."